In this exploratory study that prospectively enrolled 9 patients with metastatic castration-resistant prostate cancer initiating a new ARSi, we found a heterogeneous response to the AR pathway modulation and in most cases discordance between PSA kinetics and whole-body PSMA PET measurements. Here, FOLH1 is linked to prostate cancer.